Compugen Ltd. is a drug discovery and development company. The initial fields of focus selected by the Company are monoclonal antibodies and therapeutic proteins to address unmet needs in the fields of oncology and immunology. Its business primarily involves collaborations covering the further development and commercialization of its discovered product candidates and various forms of research and discovery agreements. The Company’s pipeline Program consists of therapeutic product candidates at various stages, ranging from validation to pre-clinical studies. Under this Pipeline Program, newly discovered molecules enter the program when they begin experimental evaluation following their in silico prediction and selection. The Pipeline Program consists of in vitro and in vivo experimental validation, including animal disease model or similar testing, followed by various preclinical activities for selected molecules for up to an additional 18 months.